Sign up for free research alerts.

Name

Email

Company

Country

Your data will never be shared with third parties, however we may send you information from time to time
about related third party products that may be of interest to you. You may contact us at any time to opt-out.

GlobalData
uses the information in this form to provide you with occasional updates on
new products and reports in accordance with your preferences. You are in
control of the communications you receive from us and you can update your
preferences anytime to make sure you are receiving information that matters to
you. Please check our
Privacy Policy
to see how we protect and manage your submitted data.

Thank you for your request.
You have been successfully added to our Research Alert list.

Chronic lymphocytic leukemia (CLL), also known as chronic lymphoid leukemia, is a type of cancer of the white blood cells (lymphocytes). CLL affects a particular lymphocyte, the B cell, which accumulates mainly in the bone marrow and blood, and normally fights infection.

CLL is the most common form of leukemia in the western world, with an average annual incidence of 5.0 per 100,000 population in people of all ages. CLL is primarily a disease of the elderly population, with less than 10% of the cases below 40 years of age.

GlobalData epidemiologists forecast an increase in the diagnosed incident cases of CLL in the 6MM, from 37,795 diagnosed incident cases in 2013 to 45,683 diagnosed incident cases in 2023, with an annual growth rate (AGR) of 2.09% during the forecast period. The 5-year diagnosed prevalent cases of CLL in the 6MM increased from 150,800 diagnosed prevalent cases in 2013 to 183,165 diagnosed prevalent cases in 2023, with an AGR of 2.15% during the forecast period.

GlobalData’s epidemiological forecast for the diagnosed incident and 5-year diagnosed prevalent cases of CLL in the 6MM is supported by age- and sex-specific data for incidence and 1- to 5-year relative survival data used for the 5-year diagnosed prevalent cases forecast are supported by country-specific, population-based studies that are nationally representative of the entire population in the respective markets. The diagnosed incident cases of CLL in each of the 6MM were further segmented by Rai stage at diagnosis to provide a more detailed analysis of the patient population, as Rai stage at diagnosis is an important factor for predicting the prognosis and treatment modalities for CLL at different stages.

Scope

The Chronic lymphocytic leukemia (CLL) EpiCast Report and EpiCast Model provide an overview of the risk factors, comorbidities, and the global and historical trends for CLL in the six major markets (6MM) (US, France, Germany, Italy, Spain, and UK). In addition, the report also includes a 10-year epidemiological forecast of the diagnosed incident cases of CLL segmented by age (beginning at 40 years and ending at 80 years and older) and sex. GlobalData epidemiologists also forecast the 5-year diagnosed prevalent cases of CLL in the 6MM. Additionally, the report provides CLL diagnosed incident cases segmented by Rai stage at diagnosis for the 6MM.

The CLL epidemiology report and model were written and developed by Masters- and PhD-level epidemiologists.

The EpiCast Report is in-depth, high quality, transparent and market-driven, providing expert analysis of disease trends in the 6MM.

The EpiCast Model is easy to navigate, interactive with dashboards, and epidemiology-based with transparent and consistent methodologies. Moreover, the model supports data presented in the report and showcases disease trends over a 10-year forecast period using reputable sources.

Reasons to buy

Develop business strategies by understanding the trends shaping and driving the global CLL market.

Saved reports

Your data will never be shared with third parties, however we may send you information from time to time
about related third party products that may be of interest to you. You may contact us at any time to opt-out.

GlobalData
uses the information in this form to provide you with occasional updates on
new products and reports in accordance with your preferences. You are in
control of the communications you receive from us and you can update your
preferences anytime to make sure you are receiving information that matters to
you. Please check our
Privacy Policy
to see how we protect and manage your submitted data.

Your enquiry has been passed on to the client services team, and you should hear back shortly.
Please contact client services for any further information:
reportstore@globaldata.com